Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer

British Journal of Cancer

Volumn 113, Issue 8, 2015, Pages 1133-1139

  Restivo, Angelo ^a   Cocco, Ivana Maria Francesca ^a   Casula, Giuseppe ^a   Scintu, Francesco ^a   Cabras, Francesco ^a   Scartozzi, Mario ^a   Zorcolo, Luigi ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

aspirin; neoadjuvant therapy; rectal cancer

Indexed keywords

ACETYLSALICYLIC ACID; CAPECITABINE; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; DIARRHEA; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROCTITIS; PROGRESSION FREE SURVIVAL; RECTUM CANCER; RISK FACTOR; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; MIDDLE AGED; NEOADJUVANT THERAPY; PREOPERATIVE CARE; PROCEDURES; PROGNOSIS; RECTAL NEOPLASMS;

AGED; ANTINEOPLASTIC AGENTS; ASPIRIN; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PREOPERATIVE CARE; PROGNOSIS; RECTAL NEOPLASMS;

EID: 84945475726     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.336     Document Type: Article

References (39)

1. Algra AM, Rothwell PM. (2012). Effects of regular aspirin on long-Term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 13(5): 518-527.
2. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. (2011). Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 Randomized Phase III Trial. J Clin Oncol. 29(20): 2773-2780.
3. Ashktorab H, Dawkins FW, Mohamed R, Larbi D, Smoot DT. (2005). Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. Dig Dis Sci. 50(6): 1025-1032.
4. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 348(10): 891-899.
5. Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJM, van Herk-Sukel MPP, Lemmens V, van den Broek CBM, Coebergh JW, Herings RMC, van de Velde CJH, Fodde R, Liefers GJ. (2012). Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 106: 1564-1570.
6. Bosset JF, Calais G, Daban A, Berger C, Radosevic-Jelic L, Maingon P, Bardet E, Pierart M, Briffaux A, Group ER. (2004). Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. Eur J Cancer. 40(2): 219-224.
7. Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Briffaux A, Collette L. (2005). Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results - EORTC 22921. J Clin Oncol. 23(24): 5620-5627.
8. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. (2006). Long-Term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 93(10): 1215-1223.
9. Chan AT, Ogino S, Fuchs CS. (2009). Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302: 649-658.
10. Din FVN, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, Stark L, Porteous ME, Campbell H, Dunlop MG. (2010). Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 59: 1670-1679.
11. Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, Davidson B, Kerr DJ, Tomlinson IP, Midgley R. (2013). Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol. 31(34): 4297-4305.
12. Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D. (2007). The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146: 365-375.
13. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107(4): 1183-1188.
14. Flossmann E, Rothwell PM, Trial BDA. (2007). Effect of aspirin on long-Term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 369(9573): 1603-1613.
15. Fuchs C, Meyerhardt JA, Heseltine DL, Niedzwiecki D, Hollis D, Chan AT, Saltz LB, Schilsky RL, Mayer RJ. (2005). Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. J Clin Oncol. 23(16): 253S-253S.
16. Gasic GJ, Gasic TB, Stewart CC. (1968). Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA. 61(1): 46-52.
17. Gerard J-P, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne P-L, Vendrely V, Francois E, De La Roche G, Bouche O, Mirabel X, Denis B, Mineur L, Berdah J-F, Mahe MA, Becouarn Y, Dupuis O, Lledo G, Montoto-Grillot C, Conroy T. (2010). Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the Phase III Trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 28(10): 1638-1644.
18. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. (2006). Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 24(28): 4620-4625.
19. Kawai K, Kitayama J, Tsuno NH, Sunami E, Watanabe T. (2013). Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer. Int J Colorectal Dis. 28(4): 527-535.
20. Kim HJ, Choi GS, Park JS, Park S, Kawai K, Watanabe T. (2015). Clinical significance of thrombocytosis before preoperative chemoradiotherapy in rectal cancer: predicting pathologic tumor response and oncologic outcome. Ann Surg Oncol. 22(2): 513-519.
21. Kim KY, Seol JY, Jeon GA, Nam MJ. (2003). The combined treatment of aspirin and radiation induces apoptosis by the regulation of bcl-2 and caspase-3 in human cervical cancer cell. Cancer Lett. 189(2): 157-166.
22. Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J, Wagner DD. (2006). Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci USA. 103(4): 855-860.
23. Kune GA, Kune S, Watson LF. (1988). Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 48(15): 4399-4404.
24. Liao XY, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun RF, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S. (2012). Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 367(17): 1596-1606.
25. Logan RFA, Grainge MJ, Shepherd VC, Armitage NC, Muir KR, Grp uT. (2008). Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 134(1): 29-38.
26. Machin D, Campbell M, Fayers P, Pinol A. (1997). Sample Size Tables for Clinical Studies. 2nd edn. Blackwell Science: Oxford, UK.
27. Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS. (2015). Aspirin and COX-2 inhibitor use in patients with Stage III colon cancer. J Natl Cancer Inst. 107(1): 1-5.
28. Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M, Spiegelman D, Cho E, Giovannucci E, Fuchs CS, Chan AT, Ogino S. (2013). Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 309(24): 2563-2571.
29. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL. (2005). Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 105(1): 178-185.
30. Patrignani P, Filabozzi P, Patrono C. (1982). Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 69(6): 1366-1372.
31. Reimers MS, Bastiaannet E, Langley RE, van Eijk R, van Vlierberghe RLP, Lemmens VEP, van Herk-Sukel MPP, van Wezel T, Fodde R, Kuppen PJK, Morreau H, van de Velde CJH, Liefers GJ. (2014). Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med. 174(5): 732-739.
32. Restivo A, Zorcolo L, Cocco IMF, Manunza R, Margiani C, Marongiu L, Casula G. (2013). Elevated CEA levels and low distance of the tumor from the anal verge are predictors of incomplete response to chemoradiation in patients with rectal cancer. Ann Surg Oncol 20: 864-871.
33. Restivo A, Zorcolo L, Marongiu L, Scintu F, Casula G. (2015). Limits of endorectal ultrasound in tailoring treatment of patients with rectal cancer. Dig Surg 32: 129-134.
34. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW. (2010). Long-Term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 376(9754): 1741-1750.
35. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. (2012). Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 379(9826): 1591-1601.
36. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 348(10): 883-890.
37. Walker AJ, Grainge MJ, Card TR. (2012). Aspirin and other non-steroidal anti-inflammatory drug use and colorectal cancer survival: a cohort study. Br J Cancer. 107(9): 1602-1607.
38. Weiss C, Arnold D, Dellas K, Liersch T, Hipp M, Fietkau R, Sauer R, Hinke A, Rodel C. (2010). Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: a pooled analysis of three prospective phase I-II trials. Int J Radiat Oncol Biol Phys. 78(2): 472-478.
39. Zorcolo L, Rosman AS, Restivo A, Pisano M, Nigri GR, Fancellu A, Melis M. (2012). Complete pathologic response after combined modality treatment for rectal cancer and long-Term survival: a meta-Analysis. Ann Surg Oncol. 19: 2822-2832.